Moleculin Accelerates Readout for Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

 Amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025

Company releases Virtual Investor "What This Means" segment discussing the amended protocol; Available here

https://www.prnewswire.com/news-releases/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-rr-acute-myeloid-leukemia-aml-pivotal-trial-to-h2-2025-302305597.html